Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06055959 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

A Phase 2 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.

Recruiting
Registry status
Phase 2
Development phase
8
Enrollment target
9
Study locations

NCT06055959: Recruiting Phase 2 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.

NCT06055959 is a Phase 2 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 8 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06055959, a Phase 2 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by UCB Biopharma SRL.

RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

Primary Outcome

Blood samples will be collected for measurement of plasma concentrations of ZLP on Day 29 predose.

Conditions Studied

Generalized Myasthenia Gravis

Interventions

  • DRUG Zilucoplan

Study Locations (9)

Other

  • Mg0014 40144 - Milan
  • Mg0014 40774 - Katowice
  • Mg0014 40218 - Warsaw
  • Mg0014 20104 - Seoul
  • Mg0014 20220 - Seoul
  • Mg0014 40735 - Glasgow
  • Mg0014 40736 - London

Illinois

  • Mg0014 50168 - Chicago

Texas

  • Mg0014 50574 - Denton

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-10-16
Est. Completion 2026-12-25
Phase Phase 2
UCB Biopharma SRL

82 total trials

What NCT06055959 shows while recruiting

NCT06055959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which Zilucoplan is the first listed.

NCT06055959 lists 9 locations in 3 states (Other, Illinois, Texas).

Frequently Asked Questions

What is clinical trial NCT06055959 about?

NCT06055959 is a clinical study titled "A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis". The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

What is the current status of trial NCT06055959?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2024-10-16. Estimated completion is 2026-12-25.

What conditions does trial NCT06055959 study?

This clinical trial studies the following conditions: Generalized Myasthenia Gravis.

What interventions are being tested in trial NCT06055959?

The interventions under investigation include: Zilucoplan (DRUG).

Who is sponsoring clinical trial NCT06055959?

This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06055959 being conducted?

This trial has 9 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Generalized Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06055959's enrollment target sits among peer trials

8 27th of 26 the lowest of 26 other Generalized Myasthenia Gravis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06055959

Source: ClinicalTrials.gov NCT06055959, the US trial registry maintained by the National Library of Medicine. NCT06055959 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.